LeMaitre Vascular (NASDAQ:LMAT) Releases Earnings Results, Misses Expectations By $0.07 EPS

LeMaitre Vascular (NASDAQ:LMAT) posted its quarterly earnings data on Tuesday. The medical instruments supplier reported $0.74 EPS for the quarter, missing analysts’ consensus estimates of $0.81 by ($0.07), FiscalAI reports. LeMaitre Vascular had a net margin of 24.35% and a return on equity of 15.36%. The firm had revenue of $70.38 million during the quarter, compared to the consensus estimate of $71.47 million. During the same period in the prior year, the company posted $0.60 earnings per share. The company’s revenue for the quarter was up 9.6% compared to the same quarter last year.

Here are the key takeaways from LeMaitre Vascular’s conference call:

• Q2 organic sales grew 10%, with growth of 12% excluding the temporary catheter recall comparison; operating income rose 26%, EPS increased 23% to $0.74, and operating margin reached a record 29%.
• Artegraft was the fastest-growing product, with sales up 34% and representing 21% of revenue. International sales are expected to reach $11 million in 2026 versus $4 million in 2025, supported by additional country approvals, longer graft sizes, and expanded commercial infrastructure.
• The company reported strong profitability and expansion in Europe, where localized warehouses and sales operations are contributing to significant shipping savings and year-over-year gross-margin gains of roughly 5 to 9 percentage points.
• Full-year revenue guidance was reduced to $276.3 million and organic growth to 11%, reflecting a stronger U.S. dollar, continued Middle East-related export delays, and slower-than-expected cardiac allograft growth because of supply constraints. Operating income guidance was lowered to $76.8 million as the revenue shortfall flows through.
• RestoreFlow and other cardiac allografts remain supply constrained, while the FDA identified additional quality-system observations at the New Jersey facility. The company says production and shipments have not been disrupted, but the QuickStitch project may now require a clinical trial, extending its timeline from quarters to years.

LeMaitre Vascular Stock Up 2.1%

Shares of LMAT traded up $2.17 during trading hours on Tuesday, hitting $105.78. The stock had a trading volume of 405,320 shares, compared to its average volume of 255,427. The company has a debt-to-equity ratio of 0.42, a current ratio of 14.32 and a quick ratio of 12.20. The firm has a 50 day simple moving average of $97.27 and a 200-day simple moving average of $99.90. The firm has a market capitalization of $2.42 billion, a P/E ratio of 39.03, a price-to-earnings-growth ratio of 2.81 and a beta of 0.52. LeMaitre Vascular has a 1-year low of $79.39 and a 1-year high of $118.01.

Insider Activity

In related news, Director Bridget A. Ross sold 5,044 shares of the stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $111.10, for a total transaction of $560,388.40. Following the completion of the sale, the director directly owned 3,942 shares of the company’s stock, valued at approximately $437,956.20. This trade represents a 56.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Trent G. Kamke sold 2,928 shares of LeMaitre Vascular stock in a transaction on Friday, May 8th. The stock was sold at an average price of $107.00, for a total value of $313,296.00. Following the sale, the insider owned 3,749 shares in the company, valued at $401,143. This trade represents a 43.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 54,453 shares of company stock valued at $5,906,174 over the last three months. Corporate insiders own 7.40% of the company’s stock.

Hedge Funds Weigh In On LeMaitre Vascular

Several institutional investors have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. grew its holdings in LeMaitre Vascular by 144.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 391,254 shares of the medical instruments supplier’s stock valued at $31,731,000 after purchasing an additional 231,157 shares during the period. Millennium Management LLC raised its stake in shares of LeMaitre Vascular by 119.8% in the first quarter. Millennium Management LLC now owns 211,222 shares of the medical instruments supplier’s stock valued at $17,722,000 after buying an additional 115,141 shares during the period. First Trust Advisors LP raised its stake in shares of LeMaitre Vascular by 13.4% in the fourth quarter. First Trust Advisors LP now owns 940,140 shares of the medical instruments supplier’s stock valued at $76,245,000 after buying an additional 111,193 shares during the period. Geode Capital Management LLC lifted its position in shares of LeMaitre Vascular by 20.1% during the 4th quarter. Geode Capital Management LLC now owns 633,089 shares of the medical instruments supplier’s stock valued at $51,351,000 after buying an additional 105,921 shares during the last quarter. Finally, Algert Global LLC lifted its position in shares of LeMaitre Vascular by 356.3% during the 3rd quarter. Algert Global LLC now owns 66,268 shares of the medical instruments supplier’s stock valued at $5,799,000 after buying an additional 51,744 shares during the last quarter. Institutional investors own 84.64% of the company’s stock.

Analyst Ratings Changes

A number of analysts have commented on the stock. Wall Street Zen cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Saturday. Citigroup reissued a “market outperform” rating on shares of LeMaitre Vascular in a research note on Tuesday, July 21st. Wells Fargo & Company lifted their target price on LeMaitre Vascular from $94.00 to $104.00 and gave the stock an “equal weight” rating in a report on Wednesday, May 6th. Citizens Jmp boosted their price target on LeMaitre Vascular from $118.00 to $127.00 and gave the company a “market outperform” rating in a research note on Wednesday, May 6th. Finally, Barrington Research restated an “outperform” rating and set a $120.00 price target on shares of LeMaitre Vascular in a report on Wednesday, June 3rd. Five investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, LeMaitre Vascular currently has an average rating of “Moderate Buy” and a consensus target price of $112.60.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.